New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:26 EDTPFE, ZTSZoetis IPO indicated to open $28.50-$29.00 on 2M shares
Zoetis (ZTS) priced 86.1M shares at $26.00. JPMorgan, BofA/Merrill and Morgan Stanley acted as joint book running managers for the offering. Note that Zoetis is the animal health unit of Pfizer (PFE), which is being spun off.
News For ZTS;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
November 18, 2014
06:39 EDTPFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
10:40 EDTZTSZoetis to host investor day
Subscribe for More Information
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:16 EDTZTSZoetis to purchase assets of Abbott Animal Health for about $255M
Subscribe for More Information
08:15 EDTZTSZoetis to purchase assets of Abbott Animal Health for about $255M
08:13 EDTPFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
07:16 EDTPFEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 14, 2014
17:14 EDTZTSPershing Square gives quarterly update on stakes
Subscribe for More Information
17:11 EDTZTSZoetis adopts poison pill to protect company from potential hostile takeover
Subscribe for More Information
14:53 EDTPFECVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:25 EDTZTSOptions with increasing implied volatility: BHI DWA ZTS
Subscribe for More Information
07:14 EDTPFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
11:28 EDTZTSOptions with increasing implied volatility: CVEO DWA ZTZ
Subscribe for More Information
09:36 EDTZTSZoetis downgraded to Neutral from Long-Term Buy at Hilliard Lyons
Subscribe for More Information
09:33 EDTZTSZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use